UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2364-1
Program Prior Authorization/Medical Necessity
Medication Tryngolza™ (olezarsen)
P&T Approval Date 2/2025
Effective Date 5/1/2025
1. Background:
Tryngolza™ (olezarsen) is an APOC-III-directed antisense oligonucleotide (ASO) indicated as
an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome
(FCS).
2. Coverage Criteriaa:
A. Initial Authorization
1. Tryngolza will be approved based on both of the following criteria:
a. Both of the following:
(1) Diagnosis of familial chylomicronemia syndrome (FCS) (i.e., monogenic
chylomicronemia, type 1 hyperlipoproteinemia)
-AND-
(2) Diagnosis has been confirmed by both of the following:
(a) One of the following:
i. Genetic confirmation of biallelic pathogenic variants (i.e.,
homozygosity, compound heterozygosity or double heterozygosity) in
FCS-causing genes (i.e., LPL, GPIHBP1, APOA5, APOC2, or LMF1)
-OR-
ii. North American FCS (NAFCS) Score ≥ 45
-AND-
(b) Untreated fasting triglyceride levels greater than or equal to 880 mg/dL
-AND-
b. Prescribed by one of the following:
(1) Cardiologist
(2) Endocrinologist
© 2025 UnitedHealthcare Services, Inc.
1
(3) Gastroenterologist
(4) Lipid specialist (lipidologist)
Authorization will be issued for 12 months
B. Reauthorization
1. Tryngolza will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Tryngolza therapy (e.g., reduction in
triglycerides, reduction in episodes of acute pancreatitis)
-AND-
b. Prescribed by one of the following:
(1) Cardiologist
(2) Endocrinologist
(3) Gastroenterologist
(4) Lipid specialist (lipidologist)
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Tryngolza [package insert]. Carlsbad, CA: Ionis Pharmaceuticals, Inc.; December 2024.
2. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, Acute
Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024;390(19):1781-
1792. doi:10.1056/NEJMoa2400201
3. Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia
syndrome: Results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898-907.e2.
doi:10.1016/j.jacl.2018.04.009
4. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-
recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-348.
doi:10.1111/joim.13016
5. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify
familial chylomicronemia syndrome (FCS) in North America. J Clin Lipidol. Published online
November 12, 2024. doi:10.1016/j.jacl.2024.09.008
© 2025 UnitedHealthcare Services, Inc.
2
Program Prior Authorization/Medical Necessity - Tryngolza™ (olezarsen)
Change Control
Date Change
2/2025 New program.
© 2025 UnitedHealthcare Services, Inc.
3